1. What did Trump say? On 22 July, Trump wrote in a social media post that the US will impose 100% tariffs on generic drugs after two years and increase this to 200% after another year. The aim is to ...

U.S. President Donald Trump's plan to impose tariffs on generic drugs will lead to patients in the U.S. paying higher prices, warned the CEO of Indian pharmaceutical company Dr Reddy's. Manufacturing ...

Apotex Health Corp. APTX-T has emerged as the only maker of generic Ozempic for Canadians for at least the next few months after a manufacturing issue at an Indian plant sidelined at least two ...

Generic drugs account for more than 90 percent of prescriptions filled in the United States. The FDA insists that they “have the same high quality, strength, purity and stability as brand-name drugs.” ...

DENVER -- A federal court dealt a perhaps chaos-inducing blow to the NCAA's new eligibility rule Friday when it ruled that all high school class of 2022 athletes who exhausted their fourth season of ...

Greg Daugherty has worked 25+ years as an editor and writer for major publications and websites. He is also the author of two books. David Kindness is a Certified Public Accountant (CPA) and an expert ...

We independently review everything we recommend. We may make money from the links on our site. Learn more› By Katie Okamoto Katie Okamoto is an editor focusing on sustainability. She’s covered the ...

A leading international generic pharmaceutical company, Sandoz Inc., and its subsidiaries agreed to tentatively enter into a major settlement that would resolve antitrust and anticompetitive ...

Lucy Lazarony is an experienced personal finance journalist and writer who got her start in 1998 writing about financial topics. She writes accessible and easy-to-understand articles about credit, ...

Generic congressional ballot questions ask voters which party’s candidate they would support if the 2026 election were held that day as well as those that ask which party voters would prefer to ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...